ZYDUS DRUG FOR MIRABEGRON

Zydus Lifesciences gets USFDA nod for generic drug

Zydus was one of the first applicants to submit a substantially complete ANDA (abbreviated new drugs application) with a paragraph IV certification for Mirabegron extended-release tablets, 25 mg and 50 mg and i, therefore,e eligible for 180 days of shared generic drug exclusivity for the drug, it added.